Topical Recombinant Human Epidermal Growth Factor for Oral Mucositis Induced by Intensive Chemotherapy with Hematopoietic Stem Cell Transplantation: Final Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Ji‐Won Kim(Kyungpook National University), Sung‐Soo Yoon(Seoul National University Hospital), Myeong Gyu Kim(Seoul National University), Youngil Koh(Seoul National University), Hyun Jung Lee(Dongguk University Ilsan Hospital), Inho Kim(Seoul National University), Seonyang Park(Seoul National University), Ji‐Hyun Kwon(Chungbuk National University Hospital), Jung Mi Oh(Seoul National University), Byoung Kook Kim(Seoul National University), Kyung Im Kim(Korea University)
Cited by 19
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Patterns of somatic structural variation in human cancer genomes
|Nature|2020|999
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2020|401